Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Components of the chromatin remodelling switch/sucrose nonfermentable (SWI/SNF) complex are recurrently mutated in tumors, suggesting that altering the activity of the complex plays a role in oncogenesis. However, the role that the individual subunits play in this process is not clear. We set out to develop an inhibitor compound targeting the bromodomain of BRD9 in order to evaluate its function within the SWI/SNF complex. Here, we present the discovery and development of a potent and selective BRD9 bromodomain inhibitor series based on a new pyridinone-like scaffold. Crystallographic information on the inhibitors bound to BRD9 guided their development with respect to potency for BRD9 and selectivity against BRD4. These compounds modulate BRD9 bromodomain cellular function and display antitumor activity in an AML xenograft model. Two chemical probes, BI-7273 (1) and BI-9564 (2), were identified that should prove to be useful in further exploring BRD9 bromodomain biology in both in vitro and in vivo settings.

Original publication

DOI

10.1021/acs.jmedchem.5b01865

Type

Journal article

Journal

J Med Chem

Volume

59

Pages

4462 - 4475

Keywords

Animals, Antineoplastic Agents, Cell Line, Tumor, Cell Proliferation, Crystallography, X-Ray, Dose-Response Relationship, Drug, Drug Design, Humans, Mice, Models, Molecular, Molecular Structure, Neoplasms, Experimental, Pyridones, Structure-Activity Relationship, Transcription Factors, Xenograft Model Antitumor Assays